• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一些稠合嘧啶类和相关杂环的合成及抗癌活性。

Synthesis and anticancer activity of some fused pyrimidines and related heterocycles.

机构信息

Chemistry Department, Faculty of Science, Princess Nora Bint, AbdulRahman University, Riyadh, Saudi Arabia.

出版信息

Saudi Pharm J. 2013 Jul;21(3):305-16. doi: 10.1016/j.jsps.2012.09.002. Epub 2012 Oct 24.

DOI:10.1016/j.jsps.2012.09.002
PMID:23960847
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3745201/
Abstract

On account of the reported anticancer of pyrimidine and condensed pyrimidine, a new pyrimido [3,2-b]-1,2,4,5-tetrazine 3a , b , 5c , d , 6, 9, pyrimido [3,2-b]-1,2,4-triazine 10, 11, pyrimido [3,2-b]-1,2,4-triazole 12 and pyrimidine derivatives 1,2a , b , 4c , d , 8, 13, 14, 15 and 16 were synthesized through different chemical reactions. Structures of all synthesized compounds were supported by spectral and elemental analyses. The obtained compounds were evaluated for their in vitro antitumor activity against human liver cancer cell line (HEPG2).

摘要

鉴于嘧啶和稠合嘧啶的抗癌报道，我们通过不同的化学反应合成了一种新的嘧啶并[3,2-b]-1,2,4,5-四嗪 3a、b、5c、d、6、9、嘧啶并[3,2-b]-1,2,4-三嗪 10、11、嘧啶并[3,2-b]-1,2,4-三唑 12 和嘧啶衍生物 1、2a、b、4c、d、8、13、14、15 和 16。所有合成化合物的结构均通过光谱和元素分析得到支持。对获得的化合物进行了体外抗人肝癌细胞系（HEPG2）的抗肿瘤活性评价。

相似文献

1
Synthesis and anticancer activity of some fused pyrimidines and related heterocycles.一些稠合嘧啶类和相关杂环的合成及抗癌活性。
Saudi Pharm J. 2013 Jul;21(3):305-16. doi: 10.1016/j.jsps.2012.09.002. Epub 2012 Oct 24.
2
Synthesis, Characterization, Antimicrobial Activity and Anticancer of Some New Pyrazolo[1,5-a]pyrimidines and Pyrazolo[5,1-c]1,2,4-triazines.一些新型吡唑并[1,5-a]嘧啶和吡唑并[5,1-c][1,2,4]三嗪的合成、表征、抗菌活性和抗癌活性。
Med Chem. 2020;16(6):750-760. doi: 10.2174/1573406415666190620144404.
3
Antitumor and antiviral activity of synthetic alpha- and beta-ribonucleosides of certain substituted pyrimido[5,4-d]pyrimidines: a new synthetic strategy for exocyclic aminonucleosides.某些取代嘧啶并[5,4-d]嘧啶的合成α-和β-核糖核苷的抗肿瘤和抗病毒活性：一种用于环外氨基核苷的新合成策略。
J Med Chem. 1989 Mar;32(3):629-37. doi: 10.1021/jm00123a022.
4
Synthesis and Pharmacological Studies of Unprecedented Fused Pyridazino[3',4':5,6][1,2,4]triazino[3,4-][1,3,4]thiadiazine Derivatives.前所未有融合的吡啶并[3',4':5,6][1,2,4]三嗪并[3,4-][1,3,4]噻二嗪衍生物的合成及药理学研究。
Molecules. 2018 Apr 27;23(5):1024. doi: 10.3390/molecules23051024.
5
Synthesis and Antimicrobial Evaluation of Thieno[2,3-d]-pyrimidine, Thieno[2',3':4,5]pyrimido[1,2-a][1,3,5]triazine, Thieno[2,3-d]-1,3-thiazine and 1,2,4-Triazole Systems.噻吩并[2,3-d]嘧啶、噻吩并[2',3':4,5]嘧啶并[1,2-a][1,3,5]三嗪、噻吩并[2,3-d]-1,3-噻嗪和1,2,4-三唑体系的合成与抗菌评价
Chem Pharm Bull (Tokyo). 2015;63(10):812-8. doi: 10.1248/cpb.c15-00463.
6
Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.新型杂环稠合嘧啶衍生物的合成、分子模拟及药理学筛选。
Eur J Med Chem. 2013 Nov;69:498-507. doi: 10.1016/j.ejmech.2013.08.042. Epub 2013 Sep 12.
7
Synthesis of Some Novel Fused Pyrimido[4″,5″:5',6']-[1,2,4]triazino[3',4':3,4] [1,2,4]triazino[5,6-b]indoles with Expected Anticancer Activity.一些新型稠合嘧啶并[4'',5'':5',6']-[1,2,4]三嗪并[3',4':3,4][1,2,4]三嗪并[5,6-b]吲哚的合成及其预期的抗癌活性。
Molecules. 2018 Mar 19;23(3):693. doi: 10.3390/molecules23030693.
8
Synthesis of thiophene and N-substituted thieno[3,2-d] pyrimidine derivatives as potent antitumor and antibacterial agents.噻吩及N-取代噻吩并[3,2-d]嘧啶衍生物的合成——作为有效的抗肿瘤和抗菌剂
Acta Pharm. 2017 Sep 1;67(3):275-292. doi: 10.1515/acph-2017-0028.
9
Synthesis, Structural Characterization and Anticancer Activity of New 5-Trifluoromethyl-2-thioxo-thiazolo[4,5-]pyrimidine Derivatives.新型5-三氟甲基-2-硫代噻唑并[4,5-]嘧啶衍生物的合成、结构表征及抗癌活性
Pharmaceuticals (Basel). 2022 Jan 13;15(1):92. doi: 10.3390/ph15010092.
10
Synthesis and anticancer evaluation of some novel pyrimido[5,4-e][1,2,4]triazines and pyrazolo[3,4-d]pyrimidine using DMF-DMA as methylating and cyclizing agent.以DMF-DMA作为甲基化和环化试剂合成某些新型嘧啶并[5,4-e][1,2,4]三嗪和吡唑并[3,4-d]嘧啶及其抗癌活性评价
Chem Cent J. 2018 May 23;12(1):64. doi: 10.1186/s13065-018-0424-3.

引用本文的文献

1
Vistas in the domain of 3-acetyl-4-hydroxy-2-quinolinone derivatives (AHQ) and their applications.3-乙酰基-4-羟基-2-喹啉酮衍生物（AHQ）领域的前景及其应用。
RSC Adv. 2025 Jun 4;15(23):18034-18088. doi: 10.1039/d5ra02813b. eCollection 2025 May 29.
2
Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective.含氮杂环作为抗癌剂：药物化学视角
Pharmaceuticals (Basel). 2023 Feb 14;16(2):299. doi: 10.3390/ph16020299.
3
Novel Steroidal[17,16-]pyrimidines Derived from Epiandrosterone and Androsterone: Synthesis, Characterization and Configuration-Activity Relationships.新型甾体[17,16-]嘧啶衍生物来源于表雄酮和雄酮：合成、表征和构效关系。
Molecules. 2023 Mar 16;28(6):2691. doi: 10.3390/molecules28062691.
4
Multicomponent synthesis of dispiroheterocycles using a magnetically separable and reusable heterogeneous catalyst.使用可磁分离且可重复使用的多相催化剂进行双螺杂环化合物的多组分合成。
RSC Adv. 2020 Oct 6;10(60):36713-36722. doi: 10.1039/d0ra06676a. eCollection 2020 Oct 1.
5
Tetrabutylammonium Bromide (TBAB) Catalyzed Synthesis of Bioactive Heterocycles.四丁基溴化铵（TBAB）催化合成生物活性杂环。
Molecules. 2020 Dec 14;25(24):5918. doi: 10.3390/molecules25245918.
6
Therapeutic potential of heterocyclic pyrimidine scaffolds.杂环嘧啶支架的治疗潜力。
Chem Cent J. 2018 Apr 4;12(1):38. doi: 10.1186/s13065-018-0406-5.
7
Synthesis, characterization and anti-breast cancer activity of new 4-aminoantipyrine-based heterocycles.新型基于 4-氨基安替比林的杂环的合成、表征及抗乳腺癌活性。
Int J Mol Sci. 2014 May 2;15(5):7539-53. doi: 10.3390/ijms15057539.

本文引用的文献

1
Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives as novel small molecule chaperone amplifiers.嘧啶并[5,4-e][1,2,4]三嗪-5,7(1H,6H)-二酮衍生物作为新型小分子伴侣增强剂
Bioorg Med Chem Lett. 2009 Aug 1;19(15):4303-7. doi: 10.1016/j.bmcl.2009.05.073. Epub 2009 May 27.
2
Targeting RSK: an overview of small molecule inhibitors.靶向RSK：小分子抑制剂概述
Anticancer Agents Med Chem. 2008 Oct;8(7):710-6. doi: 10.2174/187152008785914770.
3
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.具有抗肿瘤活性的高亲和力叶酸受体特异性甘氨酰胺核糖核苷酸甲酰基转移酶抑制剂的合成与发现。
J Med Chem. 2008 Aug 28;51(16):5052-63. doi: 10.1021/jm8003366. Epub 2008 Aug 5.
4
Molecular modeling study and synthesis of novel pyrrolo[2,3-d]pyrimidines and pyrrolotriazolopyrimidines of expected antitumor and radioprotective activities.具有预期抗肿瘤和辐射防护活性的新型吡咯并[2,3 - d]嘧啶和吡咯并三唑并嘧啶的分子建模研究与合成
Bioorg Med Chem. 2008 Mar 1;16(5):2391-402. doi: 10.1016/j.bmc.2007.11.072. Epub 2007 Nov 29.
5
Cytotoxicity of three new triazolo-pyrimidine derivatives against the plant trypanosomatid: Phytomonas sp. isolated from Euphorbia characias.三种新型三唑并嘧啶衍生物对从大戟属植物中分离出的植物锥虫：Phytomonas sp. 的细胞毒性。
Mem Inst Oswaldo Cruz. 2004 Oct;99(6):651-6. doi: 10.1590/s0074-02762004000600021. Epub 2004 Nov 18.
6
Therapeutic potential of new Pt(II) and Ru(III) triazole-pyrimidine complexes against Leishmania donovani.新型铂（II）和钌（III）三唑 - 嘧啶配合物对杜氏利什曼原虫的治疗潜力
Pharmacology. 2005 Jan;73(1):41-8. doi: 10.1159/000081073. Epub 2004 Sep 27.
7
Antiviral activity of medicinal plants of Nilgiris.尼尔吉里药用植物的抗病毒活性
Indian J Med Res. 2004 Jul;120(1):24-9.
8
Ring opening of nucleoside 1',2'-epoxides with organoaluminum reagents: stereoselective entry to ribonucleosides branched at the anomeric position.用有机铝试剂使核苷1',2'-环氧化物开环：立体选择性合成异头位分支的核糖核苷。
J Org Chem. 2004 Mar 19;69(6):1831-6. doi: 10.1021/jo030262u.
9
Cyclic PNA-based compound directed against HIV-1 TAR RNA: modelling, liquid-phase synthesis and TAR binding.针对HIV-1 TAR RNA的环状肽核酸类化合物：建模、液相合成及与TAR的结合
Org Biomol Chem. 2004 Jan 7;2(1):74-9. doi: 10.1039/b311775h. Epub 2003 Nov 27.
10
Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity.鉴定一类具有蛋白酪氨酸磷酸酶抑制活性的新型口服活性嘧啶并[5,4 - 3][1,2,4]三嗪 - 5,7 - 二胺基降糖剂。
Bioorg Med Chem Lett. 2003 Sep 1;13(17):2895-8. doi: 10.1016/s0960-894x(03)00623-1.